logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Ying-Chun Shen

National Taiwan University Cancer Center
H指数:31
被引数:4,107

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma

台湾肝癌协会关于中晚期肝细胞癌的管理共识指南

CLINICAL AND MOLECULAR HEPATOLOGY
IF16.9
2025-10-011
OAAI
Lee, I-Cheng; Wang, Hung-Wei; Teng, Wei; Lin, Tsung-Jung; Chen, Chien-Hung; Lai, Hsueh-Chou; Lee, Teng-Yu; Chang, Ching-Wei; Hung, Chao-Hung; Dai, Chia-Yen; Hung, Yi-Ping; Shen, Ying-Chun; Su, Chien-Wei; Ho, Ming-Chih; Lee, Wei-Chen; Chau, Gar-Yang; Ting, Chin-Tsung; Liang, Po-Chin; Liu, Chien-An; Chang, Pi-Yi; Chen, Kuan-Yang; Lin, Shi-Ming; Chen, Li-Tzong; Huang, Yi-Hsiang
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression

晚期肝细胞癌的免疫治疗后持久反应的结果-强调局部区域治疗的寡进展

LIVER CANCER
IF9.1
2024-02-010
OAAI
Liu, Tsung-Hao; Chen, San-Chi; Rau, Kun-Ming; Lu, Li-Chun; Lin, Po-Ting; Su, Yung-Yeh; Teng, Wei; Lai, Shiue-Wei; Yeh, Ren-Hua; Kao, Tsui-Mai; Lee, Pei-Chang; Wu, Chi-Jung; Chen, Chien-Hung; Hsu, Chih-Hung; Lin, Shi-Ming; Huang, Yi-Hsiang; Chen, Li-Tzong; Cheng, Ann-Lii; Shen, Ying-Chun
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2022-01-2029
OAAI
Zucali, Paolo Andrea; Lin, Chia-Chi; Carthon, Bradley C.; Bauer, Todd M.; Tucci, Marcello; Italiano, Antoine; Iacovelli, Roberto; Su, Wu-Chou; Massard, Christophe; Saleh, Mansoor; Daniele, Gennaro; Greystoke, Alastair; Gutierrez, Martin; Pant, Shubham; Shen, Ying-Chun; Perrino, Matteo; Meng, Robin; Abbadessa, Giovanni; Lee, Helen; Dong, Yingwen; Chiron, Marielle; Wang, Rui; Loumagne, Laure; Lepine, Lucie; de Bono, Johann
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma

肝细胞癌患者肠道菌群与免疫检查点抑制剂疗效相关性的探索性研究

JOURNAL OF HEPATOCELLULAR CARCINOMA
IF3.4
2021-07-0119
OAAI
Shen, Ying-Chun; Lee, Pei -Chang; Kuo, Yu-Lun; Wu, Wei -Kai; Chen, Chieh-Chang; Lei, Chengh-Hau; Yeh, Ching-Ping; Hsu, Chiun; Hsu, Chih-Hung; Lin, Zhong-Zhe; Shao, Yu-Yun; Lu, Li-Chun; Liu, Tsung-Hao; Chen, Chien-Hung; Wu, Ming-Shiang; Huang, Yi-Hsiang; Cheng, Ann-Lii
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

泛亚适应ESMO临床实践指南，用于管理中晚期/复发性肝细胞癌患者: 由CSCO，ISMPO，JSMO，KSMO，MOS和SSO认可的tos-esmo倡议

ANNALS OF ONCOLOGY
IF65.4
2020-03-01154
OAAI
Chen, L-T; Martinelli, E.; Cheng, A-L; Pentheroudakis, G.; Qin, S.; Bhattacharyya, G. S.; Ikeda, M.; Lim, H-Y; Ho, G. F.; Choo, S. P.; Ren, Z.; Malhotra, H.; Ueno, M.; Ryoo, B-Y; Kiang, T. C.; Tai, D.; Vogel, A.; Cervantes, A.; Lu, S-N; Yen, C-J; Huang, Y-H; Chen, S-C; Hsu, C.; Shen, Y-C; Tabernero, J.; Yen, Y.; Hsu, C-H; Yoshino, T.; Douillard, J-Y

研究方向

暂未获取到该数据
A
Ann‐Lii Cheng
H 指数:102论文数:1,290被引数:7.5万
C
Chiun Hsu
H 指数:56论文数:410被引数:1.8万
C
Chih‐Hung Hsu
H 指数:52论文数:520被引数:1.6万
Y
Yu‐Yun Shao
H 指数:35论文数:245被引数:3,442
L
Li‐Chun Lu
H 指数:24论文数:91被引数:1,640
Z
Zhong‐Zhe Lin
H 指数:24论文数:91被引数:1,875
T
Tsung‐Hao Liu
H 指数:19论文数:44被引数:1,493
D
Da‐Liang Ou
H 指数:23论文数:140被引数:1,721
F
Fu‐Chang Hu
H 指数:45论文数:172被引数:5,815
Y
Yi‐Hsiang Huang
H 指数:63论文数:824被引数:2.2万